Vitreomacular traction is what happens when the gel inside the eye doesn’t let go of the macula completely. The pull it creates is gradual, often subtle at first, and occasionally resolves on its own. When it doesn’t, the consequences for central vision can be significant.
As the eye ages, the vitreous gel that fills most of the eye slowly shrinks and liquefies. In most people this leads to a clean separation from the retina – the posterior vitreous detachment that causes floaters and flashes. In some, the vitreous remains stuck to the macula, the central part of the retina responsible for reading and detailed vision. This persistent attachment creates traction – a mechanical pull on delicate retinal tissue. Vitreomacular traction, or VMT, describes this specific scenario: an incomplete posterior vitreous detachment with a focal adhesion at the macula that is distorting or threatening to damage it.
What You Need to Know About Vitreomacular Traction
- VMT occurs when the vitreous gel remains attached to the macula during an otherwise incomplete posterior vitreous detachment
- The traction can distort macular architecture, cause visual symptoms ranging from mild metamorphopsia to significant central vision loss, and potentially lead to macular hole formation
- OCT is the key diagnostic tool – it reveals the precise anatomy of the vitreoretinal interface in a way that was impossible before its development
- Spontaneous release of the vitreous adhesion occurs in around 25–40% of cases, resolving the traction without treatment
- For cases that need intervention, options include an injection of ocriplasmin (pharmacological vitreolysis) and vitrectomy surgery
- VMT exists on a spectrum with epiretinal membrane and macular hole – understanding where a given patient sits on that spectrum guides treatment decisions
How VMT Develops
The posterior vitreous detachment process doesn’t always go smoothly. In the vast majority of people it separates cleanly, the vitreous collapsing away from the retina and leaving behind a ring-shaped floater. But in some eyes – particularly those with stronger adhesion at the macula – the separation stalls. The vitreous peels away from the peripheral retina but remains stuck centrally, tethered to the fovea or the small area immediately surrounding it.
That tethered attachment doesn’t just sit there passively. The vitreous continues to contract, pulling the foveal tissue anteriorly – toward the centre of the eye. This mechanical stress is what defines VMT. The consequences depend on the size and strength of the adhesion, the anatomy of the individual eye, and time.
The VMT spectrum
VMT doesn’t exist in isolation. It sits at a point on a broader spectrum of vitreoretinal interface disorders:
- Vitreous attached to the macula but no retinal distortion
- Asymptomatic or nearly so
- May progress to VMT or resolve spontaneously
- Observation is appropriate – no treatment needed
- Identified on OCT as incidental finding
- Attachment with demonstrable retinal distortion on OCT
- Symptoms: metamorphopsia, reduced acuity, micropsia
- Risk of progression to macular hole
- Treatment decision depends on symptoms and rate of progression
- Spontaneous resolution possible but less likely than VMA
At the more severe end, VMT can lead to a full-thickness macular hole if the traction tears through the foveal tissue. Epiretinal membrane – a sheet of fibrous tissue growing on the retinal surface – frequently develops alongside VMT, compounding the distortion.
Symptoms
VMT symptoms stem directly from distortion of the fovea, the tiny region responsible for the sharpest central vision. The most characteristic symptom is metamorphopsia – straight lines appearing wavy or bent. Reading becomes difficult when words look distorted even with correct spectacle correction. A central blurred or grey patch may develop. Objects can appear smaller than they should (micropsia). Some patients describe an overall dimming or reduced contrast in the affected eye.
Mild cases can be surprisingly easy to miss, particularly if the fellow eye compensates. Many patients first notice symptoms when covering one eye for an unrelated reason and discovering the difference. Others are identified during routine OCT scanning done for other indications.
Diagnosis
OCT has completely changed how this condition is diagnosed and managed. Before OCT became widespread, VMT was frequently missed or diagnosed late. A good-quality OCT scan of the macula shows the vitreoretinal interface directly, revealing the adhesion, the degree of retinal distortion, and any associated changes like cyst formation or epiretinal membrane. The foveal contour, normally a smooth concave depression, becomes distorted in proportion to the traction applied.
The ophthalmologist will also assess visual acuity, perform an Amsler grid test to characterise the metamorphopsia, and look for associated findings on dilated fundus examination. Repeat OCT over weeks to months is used to monitor for spontaneous resolution or progression – this serial imaging is what guides the timing of intervention.
Treatment
Watch and wait – appropriate for many patients
Because spontaneous resolution occurs in a meaningful proportion of cases, initial observation is reasonable for patients with mild symptoms and preserved visual acuity. Serial OCT monitoring – typically every 2–3 months – tracks whether the adhesion is changing. If vision remains good and there’s no sign of worsening distortion or threatened macular hole formation, continued monitoring is a valid and common management path.
Pharmacological vitreolysis – a non-surgical option
Ocriplasmin (Jetrea) is an enzyme injected into the vitreous that cleaves proteins at the vitreoretinal interface, promoting separation of the vitreous from the retina. It works best in eyes with a focal, small adhesion without a concurrent epiretinal membrane. Success rates for achieving full VMT release are moderate – around 25–40% in suitable patients – but for those it works in, it avoids surgery entirely. Side effects include transient vision changes and, rarely, more significant complications. Patient selection matters considerably.
The definitive treatment for significant VMT
Pars plana vitrectomy removes the vitreous gel and directly releases the traction by peeling the posterior vitreous cortex from the macular surface. For patients with persistent VMT, worsening symptoms, or development of a macular hole, vitrectomy offers the highest rate of anatomical and visual success. The surgery is performed under local anaesthesia, usually as a day case, by a retinal surgeon. Recovery depends on what additional steps are needed – if a macular hole has already formed, a gas bubble and face-down positioning will be required.
VMT, Macular Hole, and Epiretinal Membrane
These three conditions overlap considerably and are frequently discussed together. VMT is the mechanical process; the others are its potential consequences.
An epiretinal membrane is a thin fibrous sheet growing on the retinal surface, often triggered by the same incomplete PVD process. It causes its own distortion and frequently coexists with VMT, making the overall picture more complex and reducing the likely response to ocriplasmin.
A macular hole is the most feared complication of untreated VMT. When the tractional force tears through the full thickness of the foveal tissue, a hole forms. This causes a distinct dense central scotoma – a black or grey spot in the centre of vision – rather than the waviness of VMT alone. Macular holes are surgically repairable in most cases when caught in time, but they represent a step-down in outcome compared to treating VMT before it progresses that far.
See Your Ophthalmologist Promptly If You Notice
- A sudden increase in distortion or a new central blind spot – this may indicate a macular hole has formed
- Rapid worsening of reading vision over days rather than weeks
- New floaters or flashes alongside the metamorphopsia
- Any change in vision in the other eye, which so far may have been compensating without you realising
VMT is not a condition that announces emergencies loudly, but macular hole formation can change quite quickly. If the pattern of your symptoms shifts, don’t wait for a scheduled follow-up appointment.
Frequently Asked Questions About Vitreomacular Traction
-
Can VMT resolve without any treatment?
Yes, in a meaningful proportion of patients. Spontaneous release of the vitreous adhesion occurs in roughly 25–40% of cases, typically within the first year of diagnosis. This is one reason why observation is a legitimate first-line approach, particularly for mild cases. Regular OCT monitoring allows the clinician to act if the situation worsens rather than resolving.
-
How quickly does VMT progress to a macular hole?
It varies considerably. Some patients have stable VMT for years without forming a hole; others progress within months. Size of the adhesion, severity of the distortion, and associated features on OCT help predict progression risk, but there’s genuine individual variability. This is why monitoring frequency is tailored to each patient rather than fixed.
-
Is the ocriplasmin injection painful?
The injection is performed under topical anaesthesia – numbing drops – so the procedure itself is not painful. A brief pressure sensation is common. In the days following, some patients experience transient visual changes including reduced acuity or colour changes, which usually resolve. These temporary effects can be disconcerting if you’re not warned about them in advance. Ask your surgeon specifically what to expect.
-
Will my vision return to normal after vitrectomy?
Most patients improve, but the extent depends on how much damage the traction has already caused to the foveal tissue. Eyes treated early, before significant structural damage, tend to do best. Eyes with longstanding VMT or associated macular hole may achieve improvement but not complete restoration. The goal is stopping further deterioration and recovering as much vision as possible.
-
Does having VMT in one eye mean the other eye is at risk?
Not directly – VMT results from an individual eye’s PVD process rather than a systemic condition. However, since both eyes will eventually go through posterior vitreous detachment, the other eye is worth monitoring, particularly if it develops symptoms of PVD. Most people with VMT in one eye do not develop it in the other.
The American Academy of Ophthalmology’s macular hole page covers the closely related condition that VMT can lead to. For a detailed review of the vitreoretinal interface and the spectrum of disorders including VMT, this published review in the Journal of Ophthalmology provides a thorough clinical overview. Further information on related retinal conditions is available through our retina subspecialty section.
Vitreomacular traction (VMT) is a tractional maculopathy caused by incomplete posterior vitreous detachment (PVD) in which the posterior vitreous cortex remains adherent to the macula. As the residual vitreous face exerts anteroposterior or oblique traction, it distorts the macular architecture, producing metamorphopsia, reduced BCVA, and structural changes visible on OCT. The International Vitreomacular Traction Study (IVTS) group defined VMT as perifoveal PVD with persistent vitreomacular adhesion within a 3 mm radius of the fovea causing macular distortion, elevation, or intraretinal structural changes. VMT exists on a spectrum with epiretinal membrane (ERM) and full-thickness macular hole (FTMH) , all three can arise from abnormal or incomplete PVD. Spontaneous release occurs in up to 50% of isolated VMT without macular hole formation. When it does not resolve, pharmacological vitreolysis with ocriplasmin or surgical vitrectomy are the management options.
Clinical Overview: Vitreomacular Traction
- IVTS classification: Vitreomacular adhesion (VMA) , perifoveal PVD, foveal attachment, no structural change. VMT , VMA plus macular distortion, elevation, or intraretinal changes. Focal VMT: adhesion width ≤1500 µm. Broad VMT: adhesion >1500 µm. Associated ERM: note if present.
- Natural history: Spontaneous release in ~40-50% of focal VMT without macular hole. Broad VMT and VMT with concurrent ERM: lower spontaneous release rates. Monitor 3-monthly with OCT.
- Ocriplasmin (Jetrea): 0.125 mg intravitreal injection , enzymatic vitreolysis. Achieves vitreomacular adhesion release in ~27% (MIVI-TRUST). Best results in focal VMT (≤1500 µm adhesion), absence of ERM, phakic lens. Macular hole closure rate approximately 40% in VMT-associated FTMH. Transient VA decrease common in first 2 weeks.
- PPV (pars plana vitrectomy): Definitive surgical treatment. 90%+ anatomical success for VMT and VMT-associated macular hole. Reserve for failed ocriplasmin, broad VMT, concurrent ERM, or significant VA loss.
- Monitoring: OCT at 1-3 monthly intervals. Document adhesion size, macular structure, and BCVA. Amsler grid home monitoring (described on the visual acuity basics page) for metamorphopsia change.
Pathophysiology
VMT arises when the posterior vitreous cortex separates from the peripheral retina and optic disc margin (partial PVD) but remains adherent to the macula and perifoveal retina. The physical force of the progressively separating vitreous creates anteroposterior traction on the fovea and parafovea. Over time this produces:
- Intraretinal cystoid changes (IRF) within the outer nuclear layer and outer plexiform layer
- Subretinal fluid (SRF) accumulation at the fovea
- Disruption of the ellipsoid zone (EZ) and retinal pigment epithelium (RPE)
- Foveal elevation and central scotoma
- Progression to lamellar macular hole or full-thickness macular hole (FTMH) if traction concentrates at the fovea
Concurrent epiretinal membrane (ERM) is common , ERM forms when glial cells and RPE cells migrate onto the ILM through micro-breaks and proliferate. ERM exerts tangential traction in addition to the anteroposterior vitreous traction, making spontaneous resolution less likely and worsening structural distortion.
Diagnosis
OCT findings: The diagnostic cornerstone. The posterior vitreous face is visible as a hyperreflective line above the retina, with a persistent point or band of attachment at the fovea or perifovea. Subclassify by adhesion width (focal ≤1500 µm vs broad), presence of intraretinal cysts, SRF, EZ disruption, ERM, and foveal contour (V-shaped, U-shaped, or open-hole configuration). Quantify BCVA and central subfield thickness (CST). Baseline OCT before any intervention is mandatory for comparison.
Clinical examination: Reduced BCVA, metamorphopsia on Amsler grid, occasionally a subtle macular reflex change visible biomicroscopically. The vitreous attachment is not visible clinically , OCT is required for diagnosis. Distinguish from diabetic macular edema or other tractional maculopathies by OCT morphology and clinical context.
Management
Observation: For focal VMT with mild symptoms and preserved VA , appropriate as initial management given the ~40-50% spontaneous release rate. Monitor with OCT every 1-3 months. Intervene if VA deteriorates, symptoms worsen significantly, or a macular hole begins to form (lamellar hole or early FTMH on OCT).
Ocriplasmin (Jetrea) , pharmacological vitreolysis: Recombinant truncated plasmin injected intravitreally (0.125 mg/0.1 mL). Cleaves fibronectin and laminin at the vitreoretinal interface, releasing the vitreous. The MIVI-TRUST trial: 26.5% of ocriplasmin patients achieved VMA/VMT release at 28 days vs 10.1% placebo. Macular hole closure (in VMT-associated FTMH): approximately 40% vs 11% placebo. Real-world results are modestly lower.
Predictors of ocriplasmin success: Focal adhesion (≤1500 µm), phakic lens, no concurrent ERM, smaller macular hole diameter. Eyes with all four positive predictors have a reported success rate above 50%. Broad VMT, pseudophakia, and concurrent ERM have poor ocriplasmin response rates , PPV is preferred.
Ocriplasmin side effects: Transient VA decrease in first 2 weeks (from subretinal fluid accumulation during release), temporary dyschromatopsia, ERG (electroretinogram) changes in a minority of cases. Most resolve within 3 months. Persistent ERG changes (photoreceptor dysfunction , also seen in retinal detachment recovery , are a recognized but uncommon adverse effect , counsel patients appropriately before injection.
Pars plana vitrectomy (PPV): Small-gauge (25G/27G) PPV with induction of complete PVD, ILM (inner limiting membrane) peeling (reduces recurrence), and gas tamponade (C3F8 or SF6) if macular hole is present. Anatomical success rate above 90% for VMT release. Visual recovery depends on pre-operative macular structure , significant EZ disruption or long-standing VMT carries a guarded visual prognosis despite successful surgery.
VMT, ERM, and Macular Hole , The Spectrum
VMT, ERM, and full-thickness macular hole (FTMH) share a common pathophysiological origin in abnormal PVD. Understanding the spectrum helps management decisions. VMA (vitreous still attached, no structural change) requires no treatment , just monitoring for progression to VMT. VMT without hole formation: observe or treat as above. Lamellar macular hole: partial-thickness foveal defect, often with concurrent ERM; manage with PPV and ILM peel. FTMH: full-thickness foveal break; PPV with ILM peel and gas tamponade is definitive. Ocriplasmin can close small FTMH associated with VMT. Macular pseudohole: the apparent foveal defect caused by ERM with preserved foveal contour , no surgical urgency unless VA is significantly impaired.
Clinical Decision Points
- Focal VMT, BCVA 6/12 or better, no ERM: Observe with 3-monthly OCT. Offer ocriplasmin if patient is symptomatic and phakic. PPV not first-line unless observation shows progression.
- Broad VMT (>1500 µm) or VMT + ERM: Skip ocriplasmin (poor response). Offer PPV with ILM peel when VA is significantly affected (<6/18) or symptoms are severe.
- VMT with associated small FTMH (<250 µm): Ocriplasmin has a ~40% macular hole closure rate. Offer as first-line in phakic patients without ERM. If ocriplasmin fails, proceed to PPV.
- VMT with large FTMH (>400 µm): PPV with ILM peel and gas tamponade directly. Face-down posturing for 1-5 days post-operatively maximizes hole closure.
- Fellow eye: If the presenting eye has VMT and the fellow eye has VMA (attached but no structural change), monitor the fellow eye 6-monthly with OCT. No treatment warranted for VMA alone.
When to Expedite Assessment
- Sudden significant increase in metamorphopsia , may signal new macular hole formation
- Acute central scotoma in known VMT , OCT urgently to assess for new FTMH
- Post-ocriplasmin: severe vision loss or new field defect , exclude subretinal hemorrhage or unexpected RD
VMT is not typically an acute emergency , but new macular hole formation in a monitored VMT eye converts the urgency. A full-thickness macular hole that is treated within the first few months of formation consistently achieves better closure rates and visual outcomes than those treated late.
Clinical Pearls: VMT
-
Ocriplasmin’s 27% success rate looks modest until you account for the 40-50% spontaneous release rate it needs to beat , and it doesn’t always beat it convincingly.
The MIVI-TRUST control arm achieved 10.1% release with sham injection. Ocriplasmin achieved 26.5%. In the real world, for focal VMT in phakic eyes without ERM, the spontaneous release rate is approximately 40-50%. The marginal benefit of ocriplasmin over observation in this best-case group is therefore smaller than the headline trial number implies. The drug is most defensible in a patient with significant symptoms who cannot tolerate the uncertainty of observation or wants to avoid surgery. It is least defensible in broad VMT, pseudophakic eyes, or VMT with ERM , where the success rate falls to near-zero and PPV is the better option.
-
ILM peeling at PPV for VMT or macular hole significantly reduces recurrence , but requires training.
The inner limiting membrane (ILM) is the basement membrane of Müller cells and the scaffold on which ERM forms. Peeling it with indocyanine green (ICG) or brilliant blue G staining removes the potential scaffold for ERM recurrence and improves macular hole closure rates. ILM peeling is now standard in most VMT/macular hole PPV procedures. The risk is a small reduction in macular sensitivity from Müller cell disruption , clinically significant in a minority of patients. In VMT without macular hole, there is debate about whether ILM peeling is necessary in all cases.
-
Not all macular cysts on OCT are VMT. Check the vitreous face carefully.
Intraretinal cysts in the outer nuclear layer can arise from VMT, diabetic macular edema, retinal vein occlusion, or chronic macular degeneration. The distinguishing feature of VMT is the visible posterior vitreous face remaining attached to the macula on OCT. In DME or RVO-related ME, the vitreous face is either absent or fully separated. Misdiagnosis leads to inappropriate anti-VEGF treatment in a condition that will not respond to it , or vice versa. Always examine the full OCT B-scan from the internal limiting membrane through to the RPE, and trace the posterior vitreous face explicitly.
Further reading: AAO Preferred Practice Pattern , Idiopathic Macular Hole (covers VMT). For the vitreoretinal context see posterior vitreous detachment and the retina subspecialty page.